Phar­ma's new 'Ber­lin De­c­la­ra­tion' seeks to re­serve vac­cines, ther­a­peu­tics in pro­duc­tion for low-in­come coun­tries

As Pfiz­er/BioN­Tech and Mod­er­na re­main re­luc­tant to share IP or pro­vide tech trans­fer to ex­pand the man­u­fac­ture of their life-sav­ing mR­NA vac­cines for Covid-19, the In­ter­na­tion­al Fed­er­a­tion of Phar­ma­ceu­ti­cal Man­u­fac­tur­ers & As­so­ci­a­tions on Tues­day un­veiled a new plan, build­ing off those Covid suc­cess­es, to en­sure more eq­ui­table pan­dem­ic pre­pared­ness.

The plan, known as the “Berlin De­c­la­ra­tion,” will be brought be­fore G7 and G20 coun­tries soon and pro­pos­es to re­serve an al­lo­ca­tion of the re­al-time pro­duc­tion of drugs, vac­cines and di­ag­nos­tics for dis­tri­b­u­tion to pri­or­i­ty pop­u­la­tions in low­er in­come coun­tries, as de­ter­mined by health au­thor­i­ties dur­ing pan­demics.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER